Oddo BHF Asset Management Sas Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR)

Oddo BHF Asset Management Sas acquired a new stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 4,738 shares of the biotechnology company's stock, valued at approximately $1,698,000.

A number of other hedge funds have also made changes to their positions in the stock. Franklin Resources Inc. lifted its holdings in shares of United Therapeutics by 97.7% during the third quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company's stock valued at $89,532,000 after purchasing an additional 123,929 shares during the last quarter. Tri Ri Asset Management Corp purchased a new stake in United Therapeutics during the third quarter valued at about $7,686,000. Tidal Investments LLC boosted its holdings in shares of United Therapeutics by 33.1% in the third quarter. Tidal Investments LLC now owns 11,272 shares of the biotechnology company's stock worth $4,039,000 after buying an additional 2,803 shares during the period. World Investment Advisors LLC acquired a new position in shares of United Therapeutics in the third quarter worth about $393,000. Finally, Sanctuary Advisors LLC increased its position in shares of United Therapeutics by 2.9% in the third quarter. Sanctuary Advisors LLC now owns 11,217 shares of the biotechnology company's stock worth $4,183,000 after acquiring an additional 321 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

United Therapeutics Stock Performance

Shares of UTHR traded up $0.20 during mid-day trading on Friday, hitting $361.81. The company's stock had a trading volume of 293,245 shares, compared to its average volume of 447,737. The stock's 50-day moving average is $369.94 and its two-hundred day moving average is $341.68. The firm has a market capitalization of $16.15 billion, a PE ratio of 15.89, a price-to-earnings-growth ratio of 1.05 and a beta of 0.54. United Therapeutics Co. has a one year low of $208.62 and a one year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $748.90 million during the quarter, compared to analysts' expectations of $722.62 million. During the same period last year, the business earned $5.38 earnings per share. United Therapeutics's quarterly revenue was up 22.9% compared to the same quarter last year. Analysts expect that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

UTHR has been the subject of several recent analyst reports. The Goldman Sachs Group raised their target price on United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a research report on Friday, November 1st. Oppenheimer raised their price objective on United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a research report on Thursday, October 31st. TD Cowen upped their target price on United Therapeutics from $350.00 to $400.00 and gave the company a "buy" rating in a report on Monday, October 21st. Jefferies Financial Group raised their price target on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a "buy" rating in a report on Monday, September 23rd. Finally, Argus upped their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, United Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $370.86.

Insider Activity at United Therapeutics

In other news, CFO James Edgemond sold 7,800 shares of the business's stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $350.00, for a total value of $2,730,000.00. Following the transaction, the chief financial officer now directly owns 6,978 shares of the company's stock, valued at $2,442,300. The trade was a 52.78 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christopher Causey sold 510 shares of the firm's stock in a transaction on Friday, November 1st. The shares were sold at an average price of $376.63, for a total value of $192,081.30. Following the sale, the director now directly owns 3,675 shares of the company's stock, valued at $1,384,115.25. This represents a 12.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 119,340 shares of company stock valued at $44,765,530 in the last 90 days. 11.90% of the stock is owned by corporate insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.